• Je něco špatně v tomto záznamu ?

A safety comparison of heparin and argatroban anticoagulation in veno-venous extracorporeal membrane oxygenation with a focus on bleeding

F. Burša, J. Máca, J. Sagan, P. Sklienka, S. Němcová, Z. Kučerová, T. Romanová, O. Jor, A. Kondé, J. Janošek, M. Frelich

. 2025 ; 35 (1) : 75-81. [pub] 20241007

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, srovnávací studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010125

Grantová podpora
FNOs/2024 Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Anticoagulation during extracorporeal membrane oxygenation (ECMO) might still lead to severe bleeding complications. Heparin is the most frequently used anticoagulant, but novel drugs could be promising. Argatroban is a new alternative to heparin. To date, no robust studies have confirmed the clear superiority of argatroban (AG) over heparin, although it has some advantages and may be safer. STUDY DESIGN AND METHODS: An observational study was conducted in all adult veno-venous ECMO patients with COVID-19-associated acute respiratory distress syndrome admitted to the University Hospital Ostrava (n = 63). They were anticoagulated with heparin in the first period and with AG in the second period, targeting the same activated partial thromboplastin time (aPTT; 45-60 s). Bleeding complications requiring transfusion and life-threatening bleeding events were evaluated. The primary objective was to compare heparin and AG in terms of bleeding, transfusion requirements and mortality-related bleeding. RESULTS: The total time on ECMO per patient was 16 days with an in-hospital mortality of 55.6%. The red blood cell consumption in the AG group (median 2.7 transfusions/week) was significantly lower than in the heparin group (median 4.2 transfusions/week, p = 0.011). Life-threatening bleeding complications were higher in the heparin group compared to the AG group (35.7% vs. 10.2%, p = 0.035), and mortality-related bleeding complications were also higher in the heparin group (21.4% vs. 2.0%, p = 0.032). DISCUSSION: Argatroban is an interesting alternative to heparin with less bleeding, less need for red blood cell transfusions and improved safety of ECMO with less mortality-related bleeding.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010125
003      
CZ-PrNML
005      
20250527090612.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/tme.13102 $2 doi
035    __
$a (PubMed)39375884
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Burša, Filip $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000197701433
245    12
$a A safety comparison of heparin and argatroban anticoagulation in veno-venous extracorporeal membrane oxygenation with a focus on bleeding / $c F. Burša, J. Máca, J. Sagan, P. Sklienka, S. Němcová, Z. Kučerová, T. Romanová, O. Jor, A. Kondé, J. Janošek, M. Frelich
520    9_
$a BACKGROUND: Anticoagulation during extracorporeal membrane oxygenation (ECMO) might still lead to severe bleeding complications. Heparin is the most frequently used anticoagulant, but novel drugs could be promising. Argatroban is a new alternative to heparin. To date, no robust studies have confirmed the clear superiority of argatroban (AG) over heparin, although it has some advantages and may be safer. STUDY DESIGN AND METHODS: An observational study was conducted in all adult veno-venous ECMO patients with COVID-19-associated acute respiratory distress syndrome admitted to the University Hospital Ostrava (n = 63). They were anticoagulated with heparin in the first period and with AG in the second period, targeting the same activated partial thromboplastin time (aPTT; 45-60 s). Bleeding complications requiring transfusion and life-threatening bleeding events were evaluated. The primary objective was to compare heparin and AG in terms of bleeding, transfusion requirements and mortality-related bleeding. RESULTS: The total time on ECMO per patient was 16 days with an in-hospital mortality of 55.6%. The red blood cell consumption in the AG group (median 2.7 transfusions/week) was significantly lower than in the heparin group (median 4.2 transfusions/week, p = 0.011). Life-threatening bleeding complications were higher in the heparin group compared to the AG group (35.7% vs. 10.2%, p = 0.035), and mortality-related bleeding complications were also higher in the heparin group (21.4% vs. 2.0%, p = 0.032). DISCUSSION: Argatroban is an interesting alternative to heparin with less bleeding, less need for red blood cell transfusions and improved safety of ECMO with less mortality-related bleeding.
650    _2
$a lidé $7 D006801
650    12
$a mimotělní membránová oxygenace $7 D015199
650    12
$a kyseliny pipekolové $x terapeutické užití $x aplikace a dávkování $7 D010875
650    12
$a arginin $x analogy a deriváty $7 D001120
650    12
$a sulfonamidy $7 D013449
650    12
$a heparin $x škodlivé účinky $7 D006493
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a krvácení $x chemicky indukované $x terapie $7 D006470
650    12
$a antikoagulancia $x škodlivé účinky $x terapeutické užití $7 D000925
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a COVID-19 $x komplikace $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a syndrom dechové tísně $x terapie $7 D012128
650    _2
$a mortalita v nemocnicích $7 D017052
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Máca, Jan $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Sagan, Jiří $u Department of Infectious Diseases, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Sklienka, Peter $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Němcová, Simona $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Kučerová, Zuzana $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Romanová, Tereza $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0332419
700    1_
$a Jor, Ondřej $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Kondé, Adéla $u Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB- Technical University of Ostrava, Ostrava, Czech Republic $u Department of the Deputy Director for Science, Research and Education, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Janošek, Jaroslav $u Center for Health Research, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Frelich, Michal $u Department of Anaesthetics, Resuscitation and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic
773    0_
$w MED00004548 $t Transfusion medicine $x 1365-3148 $g Roč. 35, č. 1 (2025), s. 75-81
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39375884 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250527090612 $b ABA008
999    __
$a ok $b bmc $g 2311478 $s 1247206
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 35 $c 1 $d 75-81 $e 20241007 $i 1365-3148 $m Transfusion medicine $n Transfus Med $x MED00004548
GRA    __
$a FNOs/2024 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20250415
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace